🚀

오늘의 열정을 계속 이어가세요!

체험은 만족하셨나요? 지식 자료를 소장하고 멋진 의료인으로 성장하세요!

Immunodeficiency Syndrome | 마이메르시 MyMerci
제안하기

Immunodeficiency Syndrome

NCLEX Review Guide: Immunodeficiency Syndrome (HIV/AIDS)

Pathophysiology

HIV Infection Process

  • HIV (Human Immunodeficiency Virus) primarily targets CD4+ T lymphocytes, which are critical components of the immune system responsible for cell-mediated immunity. The virus binds to CD4 receptors and CCR5 or CXCR4 co-receptors, allowing viral entry and subsequent replication within the cell.
  • HIV infection progresses through several stages: acute infection (characterized by flu-like symptoms), clinical latency (asymptomatic period), and AIDS (Acquired Immunodeficiency Syndrome) when CD4 count falls below 200 cells/mm³ or opportunistic infections develop.

Key Points

  • HIV specifically targets and destroys CD4+ T cells, gradually compromising the immune system.
  • A CD4 count below 200 cells/mm³ is diagnostic for AIDS classification.
  • Viral load indicates the amount of HIV RNA in the blood and is used to monitor treatment effectiveness.

Transmission

  • HIV is transmitted through direct contact with infected body fluids including blood, semen, vaginal secretions, and breast milk. The most common routes of transmission are unprotected sexual contact, sharing contaminated needles, mother-to-child transmission during pregnancy/delivery/breastfeeding, and exposure to infected blood.
  • HIV is NOT transmitted through casual contact such as handshakes, hugging, sharing food/drinks, or insect bites.

Key Points

  • Highest risk activities include unprotected anal intercourse, sharing needles, and percutaneous needlestick injuries.
  • Maternal-to-child transmission can be reduced to less than 1% with appropriate antiretroviral therapy.

Clinical Manifestations

Acute HIV Infection

  • Acute HIV infection, occurring 2-4 weeks after exposure, presents with flu-like symptoms including fever, fatigue, pharyngitis, lymphadenopathy, myalgia, and maculopapular rash. These symptoms typically last 1-2 weeks and often go unrecognized as HIV infection.
  • During this phase, viral replication is extensive with high viral loads, making individuals highly infectious despite negative antibody tests (window period).

Key Points

  • Acute HIV symptoms are often mistaken for influenza or mononucleosis.
  • The window period (time between infection and detectable antibodies) can last 3-12 weeks.

AIDS-Defining Conditions

  • AIDS is diagnosed when a person with HIV develops one or more opportunistic infections or certain cancers, or when CD4 count drops below 200 cells/mm³. Common opportunistic infections include Pneumocystis jirovecii pneumonia (PJP), candidiasis, toxoplasmosis, and cryptococcal meningitis.
  • AIDS-defining malignancies include Kaposi's sarcoma, non-Hodgkin lymphoma, and invasive cervical cancer. These conditions rarely occur in individuals with intact immune systems.

Key Points

  • PJP is one of the most common opportunistic infections, presenting with nonproductive cough, fever, and dyspnea.
  • Kaposi's sarcoma presents as purplish-brown lesions on the skin and mucous membranes.
  • Wasting syndrome (involuntary weight loss >10% of baseline) is an AIDS-defining condition.

Clinical Scenario

A 32-year-old male presents with persistent fever, night sweats, unexplained weight loss (15 lbs in 2 months), and white patches in his mouth. Laboratory results show CD4 count of 175 cells/mm³. The white patches are diagnosed as oral candidiasis. This presentation is consistent with AIDS, and the patient should be started on antiretroviral therapy immediately along with prophylaxis for opportunistic infections.

Diagnosis and Assessment

HIV Testing

  • HIV diagnosis involves a two-step testing process: initial screening with an antibody/antigen test, followed by confirmatory testing if positive. Fourth-generation tests detect both HIV antibodies and p24 antigen, reducing the window period to approximately 2 weeks.
  • Rapid tests provide results in 20-30 minutes with high sensitivity and specificity, while nucleic acid tests (NATs) detect viral RNA directly and can identify infection as early as 10-33 days after exposure.

Key Points

  • Pre- and post-test counseling is essential for all HIV testing.
  • False negatives can occur during the window period; retesting may be necessary for high-risk exposures.

Monitoring Parameters

  • CD4 count and viral load are the primary laboratory values used to monitor HIV progression and treatment effectiveness. CD4 count reflects immune function (normal range: 500-1,600 cells/mm³), while viral load measures the amount of HIV RNA in the blood.
  • Additional monitoring includes complete blood count, liver and kidney function tests, lipid profile, glucose levels, and screening for co-infections (hepatitis, tuberculosis, sexually transmitted infections).

Key Points

  • The goal of treatment is to achieve viral suppression (undetectable viral load) and increase CD4 counts.
  • Viral load testing is typically performed every 3-6 months during stable treatment.

Treatment

Antiretroviral Therapy (ART)

  • Antiretroviral therapy is recommended for all individuals diagnosed with HIV, regardless of CD4 count or clinical stage. Current guidelines recommend combination therapy with at least three drugs from at least two different drug classes to prevent resistance.
  • Common antiretroviral drug classes include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and entry inhibitors.

Key Points

  • ART should be initiated as soon as possible after diagnosis to prevent disease progression and reduce transmission risk.
  • Medication adherence of >95% is critical to prevent viral resistance.
  • Single-tablet regimens improve adherence and are preferred when possible.

Common Antiretroviral Medications

Drug Class Examples Mechanism Common Side Effects
NRTIs Tenofovir, Emtricitabine, Lamivudine Block reverse transcriptase enzyme Lactic acidosis, hepatomegaly, lipoatrophy
NNRTIs Efavirenz, Rilpivirine Bind to reverse transcriptase enzyme Rash, neuropsychiatric symptoms
PIs Darunavir, Atazanavir Block protease enzyme GI intolerance, lipid abnormalities
INSTIs Dolutegravir, Raltegravir Block integrase enzyme Insomnia, headache, weight gain
Entry Inhibitors Maraviroc, Enfuvirtide Block viral entry into cells Injection site reactions (enfuvirtide)

Opportunistic Infection Prophylaxis

  • Prophylactic medications are prescribed based on CD4 count to prevent common opportunistic infections. For CD4 counts <200 cells/mm³, trimethoprim-sulfamethoxazole (TMP-SMX) is recommended to prevent Pneumocystis pneumonia (PJP).
  • Additional prophylaxis may be indicated for toxoplasmosis (CD4 <100 cells/mm³), Mycobacterium avium complex (CD4 <50 cells/mm³), and fungal infections depending on exposure risk and geographic location.

Key Points

  • Prophylaxis can be discontinued when CD4 counts increase and remain above threshold levels for at least 3-6 months with viral suppression.
  • TMP-SMX prophylaxis also provides protection against toxoplasmosis and some bacterial infections.

Important Alert

Patients taking antiretroviral medications often experience significant drug-drug interactions. Always check for interactions before starting any new medication, including over-the-counter drugs and herbal supplements. Protease inhibitors and NNRTIs have the highest potential for interactions as they affect cytochrome P450 enzymes.

Nursing Care

Assessment Priorities

  • Comprehensive nursing assessment for patients with HIV includes monitoring for signs of opportunistic infections, medication side effects, and treatment adherence. Key assessments include vital signs, weight, skin integrity, oral cavity examination, respiratory status, and neurological function.
  • Psychosocial assessment is crucial, including evaluation of support systems, mental health status, substance use, and ability to perform activities of daily living.

Key Points

  • Regular assessment of skin and mucous membranes for lesions, rashes, or infections.
  • Monitor for signs of medication toxicity including hepatotoxicity, nephrotoxicity, and metabolic abnormalities.
  • Assess for depression and anxiety, which are common in HIV patients.

Nursing Interventions

  1. Provide medication education, emphasizing the importance of strict adherence to prevent resistance.
  2. Teach patients to recognize and report signs of opportunistic infections promptly.
  3. Implement appropriate infection control measures, including standard precautions.
  4. Promote adequate nutrition and hydration to support immune function.
  5. Facilitate access to support services, including case management, mental health services, and support groups.
  6. Provide education about transmission prevention, including safer sex practices and harm reduction for substance users.

Key Points

  • Use teach-back method to confirm patient understanding of complex medication regimens.
  • Develop individualized adherence strategies based on patient's lifestyle and barriers.

Memory Aid: HAART Regimen Components

Remember the main antiretroviral drug classes with "PIN-E":

  • Protease Inhibitors
  • Integrase Inhibitors
  • Nucleosides/Nucleotides (NRTIs) and Non-nucleosides (NNRTIs)
  • Entry Inhibitors

Prevention

Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP)

  • Pre-exposure prophylaxis (PrEP) involves taking antiretroviral medications by HIV-negative individuals at high risk of acquiring HIV. When taken consistently, PrEP reduces the risk of HIV infection by about 99% for sexual transmission and at least 74% for injection drug users.
  • Post-exposure prophylaxis (PEP) is emergency antiretroviral treatment started within 72 hours after potential HIV exposure to prevent infection. PEP consists of a 28-day course of antiretroviral drugs and is most effective when started as soon as possible after exposure.

Key Points

  • PrEP requires regular HIV testing, medication adherence counseling, and monitoring for side effects.
  • PEP must be initiated within 72 hours of exposure, preferably within 24 hours.
  • Both PrEP and PEP should be combined with other prevention strategies, including condom use.

Patient Education for Prevention

  • Comprehensive HIV prevention education includes information about safer sex practices, harm reduction for injection drug users, and the importance of regular testing. Consistent and correct condom use significantly reduces HIV transmission risk during sexual activity.
  • For HIV-positive individuals, education about "treatment as prevention" is essential, as maintaining viral suppression with antiretroviral therapy prevents transmission to sexual partners (Undetectable = Untransmittable or U=U).

Key Points

  • Individuals with undetectable viral loads have effectively no risk of sexually transmitting HIV to partners.
  • Needle exchange programs and substance abuse treatment reduce transmission among injection drug users.

Commonly Confused Points

HIV vs. AIDS

HIV AIDS
The virus that causes infection Advanced stage of HIV infection
May be asymptomatic for years Characterized by opportunistic infections or CD4 <200 cells/mm³
Diagnosed by detecting antibodies or viral RNA Diagnosed when specific clinical criteria are met in HIV+ individual
All stages require antiretroviral therapy Requires ART plus prophylaxis for opportunistic infections

Window Period vs. Clinical Latency

Window Period Clinical Latency
Time between infection and detectable antibodies Asymptomatic period after initial infection
Typically 3-12 weeks Can last 8-10+ years without treatment
Person may test negative despite being infected Person tests positive but may have few or no symptoms
High viral load, highly infectious Viral replication continues with gradual CD4 decline

Common Misconceptions

  • Misconception: HIV can be transmitted through casual contact like sharing utensils or hugging. Reality: HIV requires direct contact with infected body fluids and cannot survive long outside the body.
  • Misconception: All HIV-positive mothers will transmit HIV to their babies. Reality: With proper medical care and antiretroviral therapy, the risk of mother-to-child transmission can be reduced to less than 1%.
  • Misconception: HIV/AIDS is no longer a serious concern with modern medications. Reality: While treatments have improved dramatically, HIV remains a serious chronic condition requiring lifelong management and can be fatal if untreated.

Common NCLEX Pitfalls

  • Confusing the mechanism of action between different antiretroviral drug classes
  • Misidentifying appropriate prophylactic medications for specific CD4 count thresholds
  • Overlooking the importance of drug-drug interactions with antiretroviral medications
  • Forgetting that standard precautions (not isolation) are appropriate for HIV-positive patients
  • Misunderstanding the window period and its implications for testing

Study Tips

Memory Aid: AIDS-Defining Conditions

Remember common AIDS-defining conditions with "CAPTIVATE":

  • Candidiasis (esophageal, bronchial, or pulmonary)
  • AIDS dementia complex
  • Pneumocystis pneumonia
  • Toxoplasmosis of the brain
  • Invasive cervical cancer
  • Viral infections (CMV, HSV)
  • Atypical mycobacteria (M. avium complex)
  • Tuberculosis (extrapulmonary)
  • Extreme wasting (>10% body weight)

Memory Aid: CD4 Count Thresholds

Remember prophylaxis thresholds with "200-100-50":

  • 200 cells/mm³: PJP prophylaxis (TMP-SMX)
  • 100 cells/mm³: Toxoplasmosis prophylaxis (TMP-SMX)
  • 50 cells/mm³: MAC prophylaxis (Azithromycin)

NCLEX Strategy for HIV/AIDS Questions

  • For medication questions, focus on understanding drug classes rather than memorizing individual medications. Know the major side effects and contraindications for each class.
  • For patient education questions, prioritize safety information, adherence strategies, and transmission prevention.
  • For assessment questions, remember that opportunistic infections present atypically and may be more severe in immunocompromised patients.
  • Apply the nursing process (assessment, diagnosis, planning, implementation, evaluation) to organize your approach to complex HIV/AIDS scenarios.

Quick Check

1. What CD4 count defines AIDS?

2. Name three antiretroviral drug classes.

3. What prophylactic medication is used to prevent PJP?

4. What is the window period in HIV testing?

5. What does U=U mean in HIV care?

Summary of Key Points

  • HIV is a retrovirus that targets CD4+ T cells, leading to progressive immune system deterioration. AIDS is diagnosed when CD4 count falls below 200 cells/mm³ or when opportunistic infections develop.
  • Transmission occurs through direct contact with infected body fluids, primarily through sexual contact, sharing needles, and mother-to-child transmission.
  • Antiretroviral therapy (ART) is recommended for all HIV-positive individuals regardless of CD4 count, using a combination of medications from different drug classes.
  • Strict medication adherence (>95%) is essential to prevent viral resistance and maintain viral suppression.
  • Prophylactic medications are prescribed based on CD4 count thresholds to prevent opportunistic infections.
  • Regular monitoring includes CD4 count, viral load, and screening for medication side effects and opportunistic infections.
  • Nursing care focuses on medication management, symptom monitoring, infection prevention, and psychosocial support.
  • Prevention strategies include PrEP, PEP, safer sex practices, and harm reduction for injection drug users.
  • Treatment as prevention (U=U) emphasizes that individuals with undetectable viral loads cannot sexually transmit HIV.

Self-Assessment Checklist

I understand the pathophysiology of HIV infection
I can explain the difference between HIV and AIDS
I know the major antiretroviral drug classes and their mechanisms
I understand opportunistic infection prophylaxis guidelines
I can identify key nursing interventions for HIV/AIDS patients
I understand prevention strategies including PrEP and PEP
I can explain the concept of U=U
I recognize common side effects of antiretroviral medications
I understand the importance of addressing psychosocial aspects of HIV care

Remember that HIV/AIDS care has evolved dramatically over the years. What was once a terminal diagnosis is now a manageable chronic condition with proper treatment. Your knowledge and compassionate care can make a significant difference in the lives of patients living with HIV. Stay current with guidelines as they continue to evolve!

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습
컨텐츠를 그만볼래?

필기노트, 하이라이터, 메모는 잘 쓰고 있어?

내보내줘
어떤 폴더에 저장할래?

컨텐츠 노트에는 총 0개의 폴더가 있어!

폴더 만들기
컨텐츠 만들기
만들기
신고했어요.

운영진이 검토할게요!

해당 유저를 차단했어요.

마이페이지에서 차단한 회원을 관리할 수 있어요.